Table 3.
Total cohort tumor detection rates using imaging screening
| HCI | U of M | Penn | Total | |
|---|---|---|---|---|
| Total cohort imaging scans, n | 180 | 186 | 125 | 491 |
| Including recurrences | ||||
| Scans with positive screens, n (%) | 26 (14%) | 8 (4%) | 15 (12%) | 49 (10%) |
| Percent true positive tumor screen found on first screen | 77% | 100% | 87% | 84% |
| Scans with recurrence of PGL/PCC, n (%) | 1 (0.56%) | 0 (0%) | 2 (1.6%) | 3 (0.61%) |
| Excluding recurrences | ||||
| Scans with positive screens, n (%) | 25 (14%) | 8 (4%) | 13(10%) | 46 (9%) |
| Percent true positive tumor screen found on first screen | 76% | 100% | 92% | 85% |
| SDHx-related tumors identified on scans, n | ||||
| PGL/PCC | 24 | 6 | 11 | 41 |
| GIST | 0 | 0 | 0 | 0 |
| RCC | 1 | 2 | 2 | 5 |
| Total cohort subjects, n | 100 | 95 | 68 | 263 |
| Including recurrences | ||||
| Subjects with true positive screens, n (%) | 25 (25%) | 8 (8%) | 14 (21%) | 47 (18%) |
| Excluding recurrences | ||||
| Subjects with true positive screens, n (%) | 24 (24%) | 8 (8%) | 13 (19%) | 45 (17%) |
| Additional information | ||||
| Total cohort imaging scans, n | 180 | 186 | 125 | 491 |
| Scans with false positive, n (%) | 0 (0%) | 4 (2%) | 0 (0%) | 4 (0.81%) |
| Scans with incidental actionable, n (%) | 24 (13%) | 26 (14%) | 25 (20%) | 75 (15%) |
| Scan with inconclusive finding, n (%) | 2 (1%) | 1 (0.54%) | 0 (0%) | 3 (0.61%) |
HCI: Huntsman Cancer Institute; U of M: University of Michigan; Penn: University of Pennsylvania
True positive means tumor was SDHx-related including PGL/PCC, RCC or GIST